Major bleeding risk among non‐valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a “real‐world” observational study in the United States

DOI Web Site Web Site Web Site 3 Citations

Gregory Y. H. Lip

Institute of Cardiovascular Sciences University of Birmingham City Hospital Birmingham UK
Xianying Pan

Bristol‐Myers Squibb Princeton NJ USA
Shital Kamble

Bristol‐Myers Squibb Princeton NJ USA
Hugh Kawabata

Bristol‐Myers Squibb Princeton NJ USA
Jack Mardekian

Pfizer, Inc. New York NY USA
Cristina Masseria

Pfizer, Inc. New York NY USA
Amanda Bruno

Bristol‐Myers Squibb Princeton NJ USA
Hemant Phatak

Bristol‐Myers Squibb Princeton NJ USA

Journal

International Journal of Clinical Practice

International Journal of Clinical Practice 70 (9), 752-763, 2016-08-23

Hindawi Limited

Back to top